Corona Remedies is launching its Rs 655 crore IPO next week. The Gujarat-based pharmaceutical firm is offering 100% of its shares. The grey market premium indicates a potential 29% upside. Investors can subscribe from December 8 to 10. The company has strong financial growth and high return ratios. Shares will list on NSE and BSE.Read More
Technical analyst Rohit Srivastava says Nifty is oversold and sitting on a crucial support at 25,900, with Bank Nifty near 59,100. A close below these levels could trigger a deeper fall, but holding them may mark a market bottom. He explains why volatility remains low, sector rotation continues, and what levels traders should watch for the next breakout.Read More
The Indian rupee has reached a new low, trading below 90 against the US dollar. This marks a significant slide for the currency. Foreign investors are continuing to withdraw funds from Indian stocks. The rupee’s decline is impacting exports and making local equities less attractive. This trend highlights economic challenges for India.Read More
Northern Arc Capital expects its return on assets (ROA) to rise to 3.7–3.8% over the next two years, driven by stronger NIMs from its expanding retail franchise and a fast-growing fee income business. MD & CEO Ashish Mehrotra outlines how credit-cost normalization, branch-led MSME growth and a rising share of direct lending will power 25–30% annual AUM growth.Read More
Biocon shares: Biocon’s Board will meet on Saturday, December 6, 2025, to decide on key proposals that could shape its growth and shareholder value. A major agenda item is a potential investment in its unlisted arm, Biocon Biologics either through cash or preferential allotment to boost its stake and support long-term expansion.Read More
Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.
